European Archives - Page 255 of 1152 - European Medical Journal

Semaglutide Reduces Hidradenitis Suppurativa Symptoms: EADV 2024

New research presented at EADV 2024 highlights semaglutide’s potential in reducing flare-ups and improving quality of life for hidradenitis suppurativa patients.

Advancing Respiratory Diagnostics with Smart Breath Testing

Cristian D’Alessandro discusses a revolutionary AI-enhanced breathalyser for detecting and monitoring COPD and other diseases.

Navigating the COVID-19 Vaccination Landscape: The Post-Pandemic Era

In this insightful three-part podcast series, six renowned experts in the field discuss the ways in which the COVID-19 vaccination…

Researchers Identify the Neurological Events that Follow TAVR

Neurologic events following TAVR are linked to worse survival outcomes. Research highlights that strokes pose the greatest mortality risk.

Sickle Cell Trait Linked to Higher Blood Clot Risk

A study has revealed an increased risk of venous thromboembolism in individuals with sickle cell trait compared to those without the trait.

Shared Insights on Treating BRAFV600-mutant Metastatic Cancers

Shared Perspectives on Targeted Therapies for Metastatic BRAFV600 Mutations. Recorded live from Barcelona, Spain, during the 2024…

Lifetime Management of Aortic Stenosis in Young Patients

The number of transcatheter aortic valve replacements/implantations (TAVR/TAVI) has nearly equalled that of the number of surgical aortic…

CSV/HSV Co-infection with Oesophageal Stricture in Young Immunocompetent Woman

The authors report the first case of oesophageal cytomegalovirus (CMV) and herpes simplex virus (HSV) co-infection in an immunocompetent…

ESC 2024 Interview: Lis Neubeck

I’ve been interested in alternative models to secondary prevention for a very long time. I’m very aware that not everybody gets access to cardiac rehabilitation, so I’ve been looking at digital models.

Cracking compliance in the US: Key points for pharma to remember

What key compliance considerations should pharma companies keep in mind before releasing new research in the US market, and how can they avoid compliance pitfalls?